S&P Futures
3,764.75 -56.50 (-1.48%) Dow Futures
30,626.00 -373.00 (-1.20%) Nasdaq Futures
11,480.25 -210.75 (-1.80%) Russell 2000 Futures
1,692.60 -28.80 (-1.67%) Crude Oil
109.46 -0.32 (-0.29%) Gold
1,812.10 -5.40 (-0.30%)
Prenetics Global Limited (PRE)
Chart Events
Performance Outlook
| Previous Close | 4.1500 |
| Open | 4.1400 |
| Bid | 0.0000 x 1200 |
| Ask | 0.0000 x 800 |
| Day's Range | 4.1300 - 4.1700 |
| 52 Week Range | 3.3900 - 8.7500 |
| Volume | |
| Avg. Volume | 103,177 |
| Market Cap | 459.453M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -11.0410 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for PRE
Related Research
- Prenetics Global LimitedCOOP: Lowering target price to $40.00MR COOPER GROUP INC has an Investment Rating of HOLD; a target price of $40.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.RatingFair ValueEconomic Moat8 days agoArgus Research
- PR Newswire
Prenetics Launches ColoClear, a Non-Invasive Stool DNA Test to Detect Early Signs of Colorectal Cancer in Hong Kong
Prenetics Group Limited (Nasdaq: PRE), a global leader in genomic and diagnostic testing, has introduced a novel, non-invasive, at-home screening test – ColoClear by Circle (ColoClear), for detecting early signs of colorectal cancer. Colorectal cancer is the second most common cancer in Hong Kong, accounting for 15.8% of total new cancers in 2019[1]. Combining advanced stool DNA technology with a faecal immunochemical test (FIT), the revolutionary test is the first line of defense against one of
- PR Newswire
Prenetics Announces First Quarter 2022 Financial Results After a Successful Listing on the Nasdaq under the Ticker "PRE"
Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced its unaudited financial results for the first quarter ended March 31, 2022. The Company recorded strong operational and financial performance driven by solid diagnostics and genetic testing demand, and is on track to achieve revenue guidance for FY2022.
- IPO-Edge.com
Video Highlights – Covid Testing The English Premier League and Beyond: Join CEOs of Prenetics, Artisan in Fireside Chat
IPO Edge and the Palm Beach Hedge Fund Association hosted a fireside chat with the CEO & Co-Founder of Prenetics Limited and the CEO & Director of Artisan Acquisition […]
